AstraZeneca (AZN)
92.77
0.00 (0.00%)
Upcoming Events
Latest Headlines
AstraZeneca (AZN) PT Lowered to $205 at Morgan Stanley
July 16, 2026 6:46 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley
July 16, 2026 4:30 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
July 14, 2026 6:54 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 14
July 14, 2026 6:37 AM - SEC Filing
AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
July 14, 2026 5:52 AM - StreetInsider
AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
July 13, 2026 7:06 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
HSBC Downgrades AstraZeneca (AZN:LN) (AZN) to Hold
July 13, 2026 2:24 AM - StreetInsider
Bernstein keeps telling clients to buy this pharma stock
July 11, 2026 4:00 AM - StreetInsider
Buy the pullback in this major pharma stock: Bernstein
July 10, 2026 9:00 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP175 at Citi
July 10, 2026 5:05 AM - StreetInsider
AstraZeneca (AZN) call put ratio 1.9 calls to 1 put with a focus on July 180 and 190 calls
July 9, 2026 2:39 PM - StreetInsider
AstraZeneca's Wainua fails primary endpoint in heart trial
July 9, 2026 6:18 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 09
July 9, 2026 6:17 AM - SEC Filing
Form 4 ASTRAZENECA PLC For: Jul 06 Filed by: Sharma Mani
July 8, 2026 4:30 PM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP165 at HSBC
July 6, 2026 1:32 AM - StreetInsider
Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
July 2, 2026 3:20 AM - StreetInsider
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
July 1, 2026 9:00 PM - PR NewsWire
Form 6-K ASTRAZENECA PLC For: Jul 01
July 1, 2026 10:11 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jul 01
July 1, 2026 10:07 AM - SEC Filing
Barclays Reiterates Overweight Rating on AstraZeneca (AZN:LN) (AZN)
June 30, 2026 4:24 AM - StreetInsider
Form 11-K ASTRAZENECA PLC For: Dec 31
June 29, 2026 2:31 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 29
June 29, 2026 6:45 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 29
June 29, 2026 6:06 AM - SEC Filing
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
June 29, 2026 2:30 AM - BizWire
AstraZeneca's Datroway recommended for EU approval in breast cancer
June 26, 2026 7:05 AM - StreetInsider
EU panel backs Datroway for metastatic breast cancer patients
June 26, 2026 7:01 AM - StreetInsider
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026 7:00 AM - BizWire
AstraZeneca and YMCA of the USA form five-year cancer care deal
June 24, 2026 9:01 AM - StreetInsider
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
June 24, 2026 9:00 AM - BizWire
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026 8:30 AM - StreetInsider
Form 4 ASTRAZENECA PLC For: Jun 08 Filed by: Sharma Mani
June 16, 2026 4:05 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 15
June 15, 2026 6:52 AM - SEC Filing
AstraZeneca unit receives FDA priority review for rare kidney disease treatment
June 15, 2026 3:00 AM - StreetInsider
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 12, 2026 6:44 PM - BizWire
AstraZeneca receives FDA approval for Truqap prostate cancer treatment
June 12, 2026 2:03 PM - StreetInsider
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
June 9, 2026 2:54 AM - StreetInsider
AstraZeneca's Ultomiris shows 46.6% reduction in kidney protein levels
June 8, 2026 3:02 AM - StreetInsider
Ultomiris shows 43% reduction in kidney protein levels in rare disease trial
June 6, 2026 7:07 AM - StreetInsider
AstraZeneca reports positive SERENA-6 trial results for camizestrant
June 2, 2026 8:02 AM - StreetInsider
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
June 2, 2026 8:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Jun 01
June 1, 2026 10:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 01
June 1, 2026 10:06 AM - SEC Filing
AstraZeneca IMFINZI combo cuts liver cancer progression risk by 30%
June 1, 2026 8:01 AM - StreetInsider
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in
June 1, 2026 8:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: May 29
May 29, 2026 6:44 AM - SEC Filing
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 28, 2026 9:18 PM - BizWire
Form 25-NSE ASTRAZENECA PLC Filed by: NEW YORK STOCK EXCHANGE LLC
May 28, 2026 2:29 PM - SEC Filing
FDA Approves Durvalumab in Combination with Bacillus Calmette-Guerin for High-Risk Non-Muscle Invasive Bladder Cancer
May 28, 2026 12:42 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 27
May 27, 2026 6:05 AM - SEC Filing
FDA extends review period for AstraZeneca breast cancer drug camizestrant
May 27, 2026 4:04 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:17 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:02 AM - SEC Filing
Form 4 ASTRAZENECA PLC For: May 20 Filed by: Sharma Mani
May 22, 2026 4:06 PM - SEC Filing
DATROWAY approved in US for first-line metastatic triple-negative breast cancer
May 22, 2026 10:17 AM - StreetInsider
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not
May 22, 2026 10:16 AM - BizWire
Daiichi Sankyo gets US approval for Datroway in metastatic breast cancer
May 22, 2026 9:30 AM - StreetInsider
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Cand
May 22, 2026 9:30 AM - BizWire
Enhertu gets EU panel backing for HER2 positive metastatic solid tumors
May 22, 2026 8:00 AM - StreetInsider
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
May 22, 2026 8:00 AM - BizWire
AstraZeneca's camizestrant wins EU panel backing for breast cancer
May 22, 2026 7:30 AM - StreetInsider
AstraZeneca to present Phase III cancer data at ASCO 2026
May 22, 2026 7:00 AM - StreetInsider
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 22, 2026 7:00 AM - BizWire
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 10:16 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 9:42 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 9:36 AM - SEC Filing
AstraZeneca's BAXFENDY wins FDA approval for resistant hypertension
May 18, 2026 7:00 AM - StreetInsider
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
May 18, 2026 7:00 AM - BizWire
AstraZeneca receives FDA approval for hypertension drug Baxfendy
May 18, 2026 5:07 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
May 15, 2026 9:52 PM - BizWire
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
May 15, 2026 6:31 PM - BizWire
Form 6-K ASTRAZENECA PLC For: May 14
May 14, 2026 7:25 AM - SEC Filing
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder
May 14, 2026 7:00 AM - BizWire
AstraZeneca drug combo shows survival benefit in bladder cancer trial
May 14, 2026 5:52 AM - StreetInsider
AstraZeneca drug meets primary endpoint in rare disease trial
May 12, 2026 6:53 AM - StreetInsider
Form 4 ASTRAZENECA PLC For: Apr 07 Filed by: Sharma Mani
May 8, 2026 4:06 PM - SEC Filing
Health officials explore restrictions on certain SSRI antidepressants - Reuters
May 8, 2026 12:04 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 10:24 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 9:15 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 9:12 AM - SEC Filing
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant
May 1, 2026 5:49 AM - StreetInsider
FDA Advisory Committee recommends TRUQAP for prostate cancer subtype
May 1, 2026 5:44 AM - StreetInsider
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
April 30, 2026 9:42 PM - BizWire
FDA Panel Votes 6-3 'no' On Astrazeneca Breast Cancer Drug
April 30, 2026 11:49 AM - StreetInsider
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
April 29, 2026 7:00 PM - PR NewsWire
Form 6-K ASTRAZENECA PLC For: Apr 29
April 29, 2026 7:23 AM - SEC Filing
AstraZeneca results: Q1 2026
April 29, 2026 7:00 AM - BizWire
AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand
April 29, 2026 6:09 AM - StreetInsider
AstraZeneca (AZN) Tops Q1 EPS by 6c; offers guidance
April 29, 2026 3:23 AM - StreetInsider
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
April 28, 2026 4:00 PM - StreetInsider
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
April 28, 2026 1:46 PM - StreetInsider
Form SCHEDULE 13G ASTRAZENECA PLC Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 28, 2026 11:33 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 28
April 28, 2026 7:32 AM - SEC Filing
AstraZeneca's BREZTRI wins US approval for asthma treatment
April 28, 2026 7:03 AM - StreetInsider
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
April 28, 2026 7:00 AM - BizWire
AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupus
April 27, 2026 7:03 AM - StreetInsider
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
April 27, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Apr 27
April 27, 2026 6:29 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 23
April 23, 2026 6:10 AM - SEC Filing
Full Article List
